{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Topical+Sirolimus",
    "query": {
      "intervention": "Topical Sirolimus"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 28,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Topical+Sirolimus&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-12T20:27:33.287Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01853423",
      "title": "Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Facial Angiofibroma"
      ],
      "interventions": [
        {
          "name": "Rapamune",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Le Bonheur Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "3 Years to 45 Years"
      },
      "enrollment_count": 11,
      "start_date": "2013-10",
      "completion_date": "2016-07",
      "has_results": false,
      "last_update_posted_date": "2016-08-19",
      "last_synced_at": "2026-09-12T20:27:33.287Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01853423"
    },
    {
      "nct_id": "NCT06653842",
      "title": "A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cutaneous Venous Malformations"
      ],
      "interventions": [
        {
          "name": "QTORIN 3.9% rapamycin anhydrous gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palvella Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-12-20",
      "completion_date": "2026-03",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-09-12T20:27:33.287Z",
      "location_count": 10,
      "location_summary": "Irvine, California • Palo Alto, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New Brighton",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06653842"
    },
    {
      "nct_id": "NCT04608448",
      "title": "Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Aging",
        "Epigenetics",
        "Inflammatory Mediators"
      ],
      "interventions": [
        {
          "name": "Rapamycin Topical Ointment",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "65 Years to 95 Years"
      },
      "enrollment_count": 22,
      "start_date": "2021-04-28",
      "completion_date": "2022-04-15",
      "has_results": true,
      "last_update_posted_date": "2023-07-19",
      "last_synced_at": "2026-09-12T20:27:33.287Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04608448"
    },
    {
      "nct_id": "NCT02240407",
      "title": "Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pompe Disease"
      ],
      "interventions": [
        {
          "name": "Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase",
          "type": "GENETIC"
        },
        {
          "name": "Rapamycin",
          "type": "DRUG"
        },
        {
          "name": "saline",
          "type": "OTHER"
        },
        {
          "name": "Rituxan",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Lidocaine",
          "type": "DRUG"
        },
        {
          "name": "LMX 4 Topical Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-10-17",
      "completion_date": "2021-08-26",
      "has_results": false,
      "last_update_posted_date": "2022-04-05",
      "last_synced_at": "2026-09-12T20:27:33.287Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02240407"
    },
    {
      "nct_id": "NCT04893486",
      "title": "CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "BCCs in Gorlin Syndrome Patients"
      ],
      "interventions": [
        {
          "name": "PTX-022",
          "type": "DRUG"
        },
        {
          "name": "Vehicle comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palvella Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2021-05-06",
      "completion_date": "2023-03-13",
      "has_results": false,
      "last_update_posted_date": "2024-08-29",
      "last_synced_at": "2026-09-12T20:27:33.287Z",
      "location_count": 14,
      "location_summary": "Scottsdale, Arizona • Hot Springs, Arkansas • Palo Alto, California + 11 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Orange Park",
          "state": "Florida"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04893486"
    },
    {
      "nct_id": "NCT06940895",
      "title": "Evaluating the Safety and Efficacy of Topical Sirolimus 0.2% to Treat Acanthosis Nigricans",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acanthosis Nigricans"
      ],
      "interventions": [
        {
          "name": "Sirolimus 0.2%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Narrows Institute for Biomedical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2025-03-01",
      "completion_date": "2025-07-18",
      "has_results": false,
      "last_update_posted_date": "2025-11-28",
      "last_synced_at": "2026-09-12T20:27:33.287Z",
      "location_count": 1,
      "location_summary": "Brooklyn, New York",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06940895"
    },
    {
      "nct_id": "NCT06239480",
      "title": "SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Microcystic Lymphatic Malformation"
      ],
      "interventions": [
        {
          "name": "QTORIN 3.9% Rapamycin Anhydrous Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Palvella Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2024-07-31",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2026-03-27",
      "last_synced_at": "2026-09-12T20:27:33.287Z",
      "location_count": 15,
      "location_summary": "Irvine, California • Palo Alto, California • Atlanta, Georgia + 12 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New Brighton",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06239480"
    },
    {
      "nct_id": "NCT02123966",
      "title": "An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Graft-versus-Host-Disease",
        "Oral Mucosal Disease Due to Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2014-07",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2018-07-24",
      "last_synced_at": "2026-09-12T20:27:33.287Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02123966"
    },
    {
      "nct_id": "NCT03363763",
      "title": "Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Angiofibroma of Face",
        "Tuberous Sclerosis"
      ],
      "interventions": [
        {
          "name": "Sirolimus 0.2%",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus 0.4%",
          "type": "DRUG"
        },
        {
          "name": "Placebo ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aucta Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 24,
      "start_date": "2017-04-12",
      "completion_date": "2023-03-24",
      "has_results": true,
      "last_update_posted_date": "2025-12-01",
      "last_synced_at": "2026-09-12T20:27:33.287Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03363763"
    },
    {
      "nct_id": "NCT07667413",
      "title": "Topical TOR-582 Treatment of Epistaxis in HHT",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia (HHT)",
        "Epistaxis"
      ],
      "interventions": [
        {
          "name": "Topical sirolimus ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2026-10",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-21",
      "last_synced_at": "2026-09-12T20:27:33.287Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07667413"
    }
  ]
}